ReviewInternational journal of molecular sciences2017
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A CD36-targeted aptamer-4-butyl-polyhydroxybenzophenone conjugate with pH-responsive release for liver delivery in MASLD.Regenerative biomaterials · 2026Article
- Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders.Bone research · 2025Review
- Computational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment.Research in pharmaceutical sciences · 2023Article
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- Aptamer functionalized nucleic acid nano drug for targeted synergistic therapy for colon cancer.Journal of nanobiotechnology · 2023Article
- DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.Cancers · 2023Review
- Spatial-Division Multiplexing Approach for Simultaneous Detection of Fiber-Optic Ball Resonator Sensors: Applications for Refractometers and Biosensors.Biosensors · 2022Article
- Ultralow Limit Detection of Soluble HER2 Biomarker in Serum with a Fiber-Optic Ball-Tip Resonator Assisted by a Tilted FBG.ACS measurement science au · 2022Article
- Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers.Frontiers in cell and developmental biology · 2022Review
- Breast Cancer Aptamers: Current Sensing Targets, Available Aptamers, and Their Evaluation for Clinical Use in Diagnostics.Cancers · 2021Review
- Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.International journal of molecular sciences · 2021Review
- Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases.Frontiers in bioengineering and biotechnology · 2021Review
- Recent advances in aptamer-based sensors for breast cancer diagnosis: special cases for nanomaterial-based VEGF, HER2, and MUC1 aptasensors.Mikrochimica acta · 2020Review
- Article
- Internalized Functional DNA Aptamers as Alternative Cancer Therapies.Frontiers in pharmacology · 2020Review
- Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.Cancer reports (Hoboken, N.J.) · 2019Review
- Detection of Breast Cancer Cells Using Acoustics Aptasensor Specific to HER2 Receptors.Biosensors · 2019Article
- Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.Journal of molecular medicine (Berlin, Germany) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common causes of cancer related deaths in women. Currently, with the development of early detection, increased social awareness and kinds of treatment options, survival rate has improved in nearly every type of breast cancer patients. However, about one third patients still have increased chances of recurrence within five years and the five-year relative survival rate in patients with metastasis is less than 30%. Breast cancer contains multiple subtypes. Each subtype could cause distinct clinical outcomes and systemic interventions. Thereby, new targeted therapies are of particular importance to solve this major clinical problem. Aptamers, often termed "chemical antibodies", are functionally similar to antibodies and have demonstrated their superiority of recognizing target with high selectivity, affinity and stability. With these intrinsic properties, aptamers have been widely studied in cancer biology and some are in clinical trials. In this review, we will firstly discuss about the global impacts and mechanisms of breast cancer, then briefly highlight applications of aptamers that have been developed for breast cancer and finally summarize various challenges in clinical translation of aptamers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.